Liderazgo en el abastecimiento de vacunas: segmentación y vivencias que afronta Latinoamérica en el contexto de la COVID-19
DOI:
https://doi.org/10.33936/qkrcs.v6i3.5185Keywords:
health management; pandemic; health services; vaccinationsAbstract
A qualitative, non-experimental, descriptive, cross-sectional study applied to discourse analysis was carried out, with the aim of being able to analyze the leadership mechanisms in the supply of vaccines of the health services that make up the countries of Latin America in the context of the COVID-19. The methodology used was comparative bibliography, with a delimitation of criteria based on the search for articles with a period of 5 years of updating in specialized health databases from July 10 to 19, 2022. The relevant articles were collected with the reference manager Mendeley, forming a personal virtual library according to the subject of study. Due to the documentary silence on the subject in question, original primary sources, redefinition of keywords, complementary searches and consultations with experts on the subject were used. The contribution of this study lies in demonstrating how the leadership mechanisms used in the health sector limited the correct supply of vaccines during the pandemic in Latin American countries. The results reflect that Colombia, Ecuador and Peru obtained almost all the available vaccines, the predominant form of acquisition was through bilateral agreements and agreements with producing countries. Argentina represented 90.24% of doses applied with coverage of 82.36% respectively. It is concluded that the leadership used in the supply of vaccines was deficient. Haiti turned out to be the country with the fewest vaccinations, due to the rejection of the government for not considering them safe, which accelerates the level of contagion and prevents greater coverage in the analyzed population.
Downloads
References
Organización Panamericana de la Salud. Salud en las Américas, edición del 2017. Resumen: panorama regional y perfiles de país. Disponible en: https://iris.paho.org/handle/10665.2/34322#:~:text=Salud%20en%20las%20Am%C3%A9ricas%2B%202017%20sigue%20documentando%20el%20progreso%20alcanzado,la%20s%C3%ADfilis%20y%20la%20tuberculosis
Organización Mundial de la Salud. Actualización de estrategias frente a la COVID-19 [Internet]. 2021. Disponible en: https://www.who.int/docs/default-source/coronaviruse/covid-strategy-update-14april2020_es.pdf
Duryea S, Pereira MA. Transparencia y equidad en la distribución de vacunas COVID-19 en América Latina y el Caribe: Preguntas claves para abordar temas de género y diversidad [Internet]. 2021:1-12. Disponible en: http://dx.doi.org/10.18235/0003120
UNESCO. Covid-19 and vaccination in Latin America and The Caribbean: Challenges, needs and opportunities [Internet]. 2021. Disponible en: https://www.unesco.org/en/articles/covid-19-and-vaccination-latin-america-and-caribbean-challenges-needs-and-opportunities
Organización Panamericana de la Salud. Introducción de la vacuna contra la COVID-19: Orientaciones para determinar los grupos prioritarios y elaborar la microplanificación [Internet]. 2021. Disponible en: https://iris.paho.org/bitstream/handle/10665.2/53250/OPSFPLIMCOVID-19210008_por.pdf?sequence=5
Díaz S, De la Cruz YN. La vacunación contra la covid-19 y su regionalización en México. RECIEN [Internet]. 2022;11(2):63-74. Disponible en: https://revista.cep.org.pe/index.php/RECIEN/article/view/6/5
Pérez G, Castilla J, Astray J, Godoy S, Tuells J, Barrabeig I, Domínguez A. Hacia el control de la COVID-19 a través de la vacunación: obstáculos, desafíos y oportunidades. Informe SESPAS 2022. Gaceta Sanitaria [Internet]. 2022;36(supl 1):s82-s86. Disponible en: https://doi.org/10.1016/j.gaceta.2022.03.002
Agostoni C, Ramacciotti K, Lopes G. Historia en tiempos pandémicos: covid-19 en Latinoamérica. Hist. cienc. saude-Manguinhos [Internet]. 2022;29(2):563-79. Disponible en: https://doi.org/10.1590/S0104-59702022000300022
James IC, Rojas JP. Vacunación contra SARS-CoV-2 / COVID-19: Actualidad y perspectivas de vacunación en Colombia. Pediatria [Internet]. 2021;54(3):105-10. Disponible en: https://doi.org/10.14295/rp.v54i3.294
Katz IT, Weintraub R., Bekker LG, Brandt A. From Vaccine Nationalism to Vaccine Equity — Finding a Path Forward. N Engl J Med [Internet]. 2021;384:1281-3. Disponible en: https://doi.org/10.1056/NEJMp2103614
Ares-Blanco S, Astier-Peña MP, Gómez-Bravo R, Fernández-García M, Bueno-Ortiz JM. Gestión de los recursos humanos y estrategias de vacunación en atención primaria en Europa en la pandemia COVID-19 [Human resource management and vaccination strategies in primary care in Europe during COVID-19 pandemic]. Aten Primaria [Internet]. 2021;53(10):102132. Disponible en: https://doi.org/10.1016/j.aprim.2021.102132
Eccleston-Turner M, Upton H. International Collaboration to Ensure Equitable Access to Vaccines for COVID-19: The ACT-Accelerator and the COVAX Facility. Milbank Q [Internet]. 2021;99(2):426-49. Disponible en: https://doi.org/10.1111/1468-0009.12503
Malca JA, Callao M. Liderazgo gerencial en las entidades gubernamentales. Revista Científica Multidisciplinar [Internet]. 2021;5(5):8718-36. Disponible en: https://doi.org/10.37811/cl_rcm.v5i5.949
Torres AG. Vacunas contra el SARS-CoV-2: ¿son una realidad para América Latina? Biomédica [Internet]. 2020;40(3):424-6. Disponible en: http://www.scielo.org.co/pdf/bio/v40n3/2590-7379-bio-40-03-424.pdf
Romero M, Sandoval M, Tamayo K, Vivas J, Viscaya C, D’Apollo R. Cobertura y cumplimiento del esquema de inmunizaciones en niños hasta 5 años, las Cuibas, estado Lara. Rev Vzlana Sal Pub [Internet]. 2018;2(1):23-30. Disponible en: https://revistas.uclave.org/index.php/rvsp/article/view/1479
Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med [Internet]. 2000;343(5):338-44. Disponible en: https://doi.org/10.1056/NEJM200008033430506
Borobia AM, Carcas AJ, Pérez-Olmeda M, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. The Lancet [Internet]. 2021;398(10295):121-30. Disponible en: https://doi.org/10.1016/S0140-6736(21)01420-3
Martínez-Baz I, Miqueleiz A, Casado I, Navascués A, Trobajo-Sanmartín C, Burgui C, Guevara M, Ezpeleta C, Castilla J, Working Group for the Study of COVID-19 in Navarra. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021. Euro Surveill [Internet]. 2021;26(21). Disponible en: https://doi.org/10.2807/1560-7917.ES.2021.26.21.2100438
Hodgson SH, Mansatta K, Mallett G, Harris V, Emary K, Pollard A. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis [Internet]. 2021;21(2):e26-e35. Disponible en: https://doi.org/10.1016/S1473-3099(20)30773-8
López J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med [Internet]. 2021;385:585-94. Disponible en: https://doi.org/10.1056/NEJMoa2108891
Swift MD, Breeher LE, Tande AJ, Tommaso CP, Hainy CM, Chu H, Murad MH, Berbari EF, Virk A. Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel. Clin Infect Dis [Internet]. 2021;73(6):e1376-e1379. Disponible en: https://dx.doi.org/10.1093/cid/ciab361
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Yanedsy Díaz Amador

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.